Company Overview - Fox Corporation is expected to report quarterly earnings of $0.96 per share, reflecting a year-over-year decline of 11.9% [3] - Revenues are anticipated to reach $4.15 billion, which is an increase of 20.5% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 4.84% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Fox is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.53% [10][11] - Fox currently holds a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Fox exceeded the expected earnings of $0.61 per share by delivering $0.96, resulting in a surprise of +57.38% [12] - Over the past four quarters, Fox has beaten consensus EPS estimates three times [13] Industry Context - E.W. Scripps, another player in the Zacks Broadcast Radio and Television industry, is expected to report a loss of $0.23 per share, indicating a year-over-year change of -130% [17] - E.W. Scripps has an Earnings ESP of 0.00% and has not beaten consensus EPS estimates in any of the last four quarters [18]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Arcturus Therapeutics despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Arcturus Therapeutics is expected to report a quarterly loss of $1.13 per share, reflecting a year-over-year change of -13% [3]. - Revenues are projected to be $38.08 million, which is a slight increase of 0.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 5% over the last 30 days, indicating a bearish sentiment among analysts [4]. - The Most Accurate Estimate for Arcturus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.49% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Arcturus was expected to post a loss of $0.34 per share but instead reported a loss of $1.11, resulting in a surprise of -226.47% [12]. - Over the past four quarters, Arcturus has beaten consensus EPS estimates three times [13]. Conclusion - Arcturus Therapeutics does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting caution for investors [16].

Company Overview - Lincoln Educational Services Corporation (LINC) is expected to report a year-over-year decline in earnings of 33.3%, with quarterly earnings projected at $0.04 per share, while revenues are anticipated to increase by 10.1% to $113.84 million [3][12]. Earnings Expectations - The upcoming earnings report is scheduled for May 12, and the stock may experience upward movement if the reported numbers exceed expectations, while a miss could lead to a decline [2][3]. - The consensus EPS estimate has been revised down by 38.24% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Most Accurate Estimate for Lincoln Educational Services is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -225%, which suggests a challenging outlook for beating the consensus EPS estimate [11][10]. - The company currently holds a Zacks Rank of 4, further complicating the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Lincoln Educational Services had an earnings surprise of +3.33%, having posted earnings of $0.31 per share against an expectation of $0.30 [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates three times [13]. Industry Comparison - In comparison, Universal Technical Institute (UTI), another player in the Zacks Schools industry, is expected to report earnings of $0.12 per share, reflecting a year-over-year decline of 14.3%, with revenues projected at $197.04 million, up 7% [17]. - UTI has an Earnings ESP of 6.12% and a Zacks Rank of 3, indicating a higher likelihood of beating the consensus EPS estimate [18].

Core Viewpoint - Regenxbio (RGNX) is anticipated to report a significant year-over-year increase in earnings and revenues for the quarter ended March 2025, which could influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on May 12, 2025, with a consensus estimate of $0.41 per share, reflecting a year-over-year increase of +129.7% [3]. - Revenues are projected to reach $109.98 million, representing a substantial increase of 604.1% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 6.26%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Regenxbio is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +57.77% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Regenxbio currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Regenxbio was expected to post a loss of $1.27 per share but actually reported a loss of $1.01, resulting in a surprise of +20.47% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Sangamo Therapeutics (SGMO) is expected to report a loss of $0.11 per share for the same quarter, with a year-over-year change of +59.3% [17]. - Sangamo's revenue is projected to be $9.17 million, up 1810.4% from the previous year [17]. - Despite a recent downward revision of 23.8% in consensus EPS estimates, Sangamo has an Earnings ESP of 27.27%, but it holds a Zacks Rank of 4 (Sell), making predictions of an earnings beat uncertain [18].

Core Viewpoint - Perrigo Company plc (PRGO) is expected to exceed earnings expectations in its first-quarter 2025 report, with a consensus estimate for sales at $1.08 billion and earnings at 53 cents per share [1]. Group 1: Upcoming Earnings Expectations - The earnings surprise history shows that Perrigo has beaten estimates in three of the last four quarters, with an average surprise of 7.78% [4]. - The Zacks Consensus Estimate for sales in the Consumer Self Care Americas (CSCA) segment is $657 million, while the model estimate is $638 million [2]. - For the Consumer Self Care International (CSCI) segment, the Zacks Consensus Estimate is $432 million, and the model estimate is $434 million [2]. Group 2: Macroeconomic Impact - An update on the expected impact of macroeconomic pressures is anticipated in the upcoming earnings report [3]. Group 3: Earnings Surprise Potential - Perrigo currently has an Earnings ESP of +2.37% and a Zacks Rank of 3, indicating a good chance of delivering an earnings beat [6][7]. - Other biotech stocks with favorable combinations for potential earnings beats include CytomX Therapeutics, argenx, and Novavax, each with varying Earnings ESPs and Zacks Ranks [8][9].

Core Viewpoint - Opus Genetics, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][3]. Financial Performance Expectations - The company is expected to post a quarterly loss of $0.34 per share, reflecting a year-over-year change of -17.2% [3]. - Revenues are projected to be $2.8 million, which represents a 63.7% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10]. Earnings Surprise History - In the last reported quarter, the company was expected to post a loss of $0.34 per share but instead reported a loss of $1.27, resulting in a surprise of -273.53% [12]. - Over the past four quarters, Opus Genetics has only beaten consensus EPS estimates once [13]. Industry Comparison - Cue Biopharma, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.14 per share for the same quarter, indicating a year-over-year change of +44% [17]. - Cue Biopharma's revenues are expected to be $2 million, up 16.3% from the previous year, with an unchanged consensus EPS estimate over the last 30 days [17][18].

Company Overview - Veren (VRN) is expected to report a year-over-year increase in earnings of +31.8% to $0.29 per share, despite a revenue decline of 12.4% to $719.9 million for the quarter ended March 2025 [3][12] - The stock's price movement will largely depend on how actual results compare to consensus estimates, with a potential for higher stock prices if results exceed expectations [1][2] Earnings Estimates and Revisions - The consensus EPS estimate for Veren has been revised 25% higher in the last 30 days, indicating a bullish sentiment among analysts [4] - The Most Accurate Estimate for Veren is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +13.79%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11] Earnings Surprise History - In the last reported quarter, Veren exceeded expectations by delivering earnings of $0.29 per share against an expected $0.24, resulting in a surprise of +20.83% [12] - Over the last four quarters, Veren has beaten consensus EPS estimates only once, indicating a mixed performance history [13] Industry Context - In the Zacks Oil and Gas - Integrated - Canadian industry, Cenovus Energy (CVE) is expected to report earnings of $0.29 per share, reflecting a year-over-year decline of -37%, with revenues projected at $9.55 billion, down 3.9% [17] - Cenovus has seen a 1.6% downward revision in its consensus EPS estimate over the last 30 days, and its Earnings ESP is currently at 0.00%, making it difficult to predict a beat against consensus estimates [18]

Core Viewpoint - The market anticipates Costamare (CMRE) will report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Costamare is expected to post quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 17.5% [3]. - Revenues are projected to be $412.67 million, down 13.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Costamare is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.80% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, especially when combined with a strong Zacks Rank [8]. - However, Costamare currently holds a Zacks Rank of 4, complicating the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Costamare exceeded the expected earnings of $0.66 per share by delivering $0.69, resulting in a surprise of +4.55% [12]. - The company has beaten consensus EPS estimates in each of the last four quarters [13]. Industry Context - In the Zacks Transportation - Shipping industry, Ardmore Shipping (ASC) is expected to report earnings of $0.15 per share, indicating a year-over-year decline of 83.7% [17]. - Ardmore Shipping's consensus EPS estimate has been revised 37.8% lower in the last 30 days, leading to an Earnings ESP of -10.35% [18].

Core Insights - Xenia Hotels & Resorts reported revenue of $288.93 million for Q1 2025, an 8% year-over-year increase, with an EPS of $0.51 compared to $0.08 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate by 5.66%, while the EPS surprise was 21.43% above the consensus estimate of $0.42 [1] Revenue Breakdown - Food and beverage revenue reached $104.70 million, surpassing the average estimate of $94.62 million, reflecting a year-over-year increase of 12.9% [4] - Room revenue was $159.87 million, exceeding the average estimate of $156.67 million, with a year-over-year change of 4.4% [4] - Other revenues totaled $24.36 million, above the estimated $22.12 million, marking a 12.8% increase compared to the previous year [4] Stock Performance - Xenia Hotels & Resorts shares returned 2.9% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - The energy sector is facing challenges due to macroeconomic uncertainty and commodity price volatility, but some companies are positioned to potentially exceed earnings expectations, which could positively impact their stock prices in the near term [1]. Sector Snapshot - Oil prices have decreased in Q1 2025, with West Texas Intermediate crude averaging $71.84 per barrel, down from $77.56 in Q1 2024, attributed to soft global demand, rising inventories, and increased non-OPEC+ production [2]. - U.S. natural gas prices have rebounded sharply, averaging $4.15 per MMBtu compared to $2.13 a year ago, driven by colder weather and growing LNG exports [2]. Earnings Expectations - S&P 500 energy firms are projected to report a 12.9% year-over-year decline in earnings and a 0.3% dip in revenues, indicating ongoing pressure on profit margins [3][5]. - This decline is an improvement from the 22.4% earnings drop in Q4 2024, but still reflects significant challenges for oil-centric companies [3][6]. Company Performance Insights - Some energy companies are expected to perform better due to effective cost management, operational efficiency, and a focus on natural gas, which may lead to earnings surprises [4][7]. - Energy Transfer (ET) has an Earnings ESP of +9.23% and a Zacks Rank 3, with earnings scheduled for release on May 6 [11][12]. - MPLX LP also has a +9.23% Earnings ESP and a Zacks Rank 3, with earnings set to be released on May 6 [12]. - Pembina Pipeline (PBA) has an Earnings ESP of +2.93% and a Zacks Rank 3, with earnings scheduled for May 8 [13]. - ConocoPhillips (COP) has an Earnings ESP of +2.76% and a Zacks Rank 3, with earnings also scheduled for May 8 [14].